Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Repeated In Vitro Fertilization Cycles for Infertility

Repeated In Vitro Fertilization Cycles for Infertility Editorial Opinion ARTICLE INFORMATION 4. Azim AA, Costantini-Ferrando M, Oktay K. premenopausal women with breast cancer: Safety of fertility preservation by ovarian a randomized trial. JAMA. 2011;306(3):269-276. Author Affiliations: Dana-Farber Cancer Institute, stimulation with letrozole and gonadotropins in Boston, Massachusetts; Brigham and Women’s 11. Moore HC, Unger JM, Phillips KA, et al; patients with breast cancer: a prospective Hospital, Harvard Medical School, Boston, POEMS/S0230 Investigators. Goserelin for ovarian controlled study. J Clin Oncol. 2008;26(16):2630- Massachusetts. protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923-932. Corresponding Author: Ann H. Partridge, MD, 5. Oktay K, Turan V, Bedoschi G, Pacheco FS, MPH, Dana-Farber Cancer Institute, Y1245, 450 12. Munhoz RR, Pereira AA, Sasse AD, et al. Moy F. Fertility preservation success subsequent to Brookline Ave, Boston, MA 02215 Gonadotropin-releasing hormone agonists for concurrent aromatase inhibitor treatment and (ahpartridge@partners.org). ovarian function preservation in premenopausal ovarian stimulation in women with breast cancer. women undergoing chemotherapy for early-stage Conflict of Interest Disclosures: The author has J Clin Oncol. 2015;33(22):2424-2429. breast cancer: a systematic review and completed and submitted the ICMJE Form for 6. Turner NH, Partridge A, Sanna G, Di Leo A, meta-analysis [published online October 1, 2015]. Disclosure of Potential Conflicts of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Repeated In Vitro Fertilization Cycles for Infertility

JAMA , Volume 314 (24) – Dec 22, 2015

Loading next page...
 
/lp/american-medical-association/repeated-in-vitro-fertilization-cycles-for-infertility-oqVflsY5Wh
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2015.17297
pmid
26717028
Publisher site
See Article on Publisher Site

Abstract

Editorial Opinion ARTICLE INFORMATION 4. Azim AA, Costantini-Ferrando M, Oktay K. premenopausal women with breast cancer: Safety of fertility preservation by ovarian a randomized trial. JAMA. 2011;306(3):269-276. Author Affiliations: Dana-Farber Cancer Institute, stimulation with letrozole and gonadotropins in Boston, Massachusetts; Brigham and Women’s 11. Moore HC, Unger JM, Phillips KA, et al; patients with breast cancer: a prospective Hospital, Harvard Medical School, Boston, POEMS/S0230 Investigators. Goserelin for ovarian controlled study. J Clin Oncol. 2008;26(16):2630- Massachusetts. protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923-932. Corresponding Author: Ann H. Partridge, MD, 5. Oktay K, Turan V, Bedoschi G, Pacheco FS, MPH, Dana-Farber Cancer Institute, Y1245, 450 12. Munhoz RR, Pereira AA, Sasse AD, et al. Moy F. Fertility preservation success subsequent to Brookline Ave, Boston, MA 02215 Gonadotropin-releasing hormone agonists for concurrent aromatase inhibitor treatment and (ahpartridge@partners.org). ovarian function preservation in premenopausal ovarian stimulation in women with breast cancer. women undergoing chemotherapy for early-stage Conflict of Interest Disclosures: The author has J Clin Oncol. 2015;33(22):2424-2429. breast cancer: a systematic review and completed and submitted the ICMJE Form for 6. Turner NH, Partridge A, Sanna G, Di Leo A, meta-analysis [published online October 1, 2015]. Disclosure of Potential Conflicts of

Journal

JAMAAmerican Medical Association

Published: Dec 22, 2015

References